Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826)

Cat. No.: HY-P992080: Data Sheet
FAQs
Technical Support

Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is a humanized monoclonal antibody targeting H7N9. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) induces antibody-dependent cellular cytotoxicity (ADCC) against cells expressing H7N9 HA. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is applicable to studies related to H7N9 avian influenza virus infection.

For research use only. We do not sell to patients.

Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) Chemical Structure

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Virus

In Vitro

Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) binds to H7N9 influenza hemagglutinin (HA) with high pH-dependent affinity via a unique pH-sensitive epitope distinct from conventional HA head antigenic sites^[1].
Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) mediates potent concentration-dependent ADCC cytotoxicity against H7N9 HA-expressing 293T cells, with greater activity than the positive control antibody CR9114 (HY-P992083)^[2].
Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) exhibits weak-to-moderate hemagglutination inhibition activity against H7N9 influenza A HA at an endpoint concentration of 5 μg/mL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) (0.5-1 mg per mouse; i.p.; single dose) confers 100% survival in BALB/c mice against lethal H7N9 virus challenge when administered either 12 hours before or 12 hours after viral exposure, while a 0.5 mg dose provides partial protection and reduces associated lung pathology^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c (female, 6-8 weeks old, 18.0 g)^[2]
Dosage:	1 mg per mouse; 0.5 mg per mouse
Administration:	i.p.; single dose
Result:	Conferred full survival under both prophylactic and therapeutic dosing; achieved 80% survival at 0.5 mg prophylactic dose; achieved 60% survival at 0.5 mg therapeutic dose. Lessened weight loss by day 9 before weight rebound at 0.5 mg prophylactic dose. Triggered weight recovery 6-8 days post-infection across all treated groups. Exhibited mild pulmonary lesions and alleviated lung/bronchial pathological damage at 0.5 mg and 1 mg for both administration modes.

Accession

C3W5S1

Target

influenza A virus hemagglutinin HA

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

SMILES

[Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826)]

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Liu WJ, et al. Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic. Front Med. 2021;15(4):507-527. [Content Brief]

[2]. Yu F, et al. A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host Microbe. 2017 Oct 11;22(4):471-483.e5. [Content Brief]